Prothena Corporation plc Stock News

Prothena Corporation plc (NASDAQ: PRTA ) presented new preclinical data from its dual Aβ/tau and tandem C-terminal α-synuclein vaccine programs in Alzheimer''s disease (AD) and Parkinson''s disease (PD), respectively. The data were presented at the International Conference on … Full story available on Benzinga.com

Announcing preclinical data for its dual Aβ/tau vaccine targeted at Alzheimer’s disease, clinical-stage biotech Prothena Corporation (PRTA) said on Wednesday that the company plans for…

DUBLIN, Ireland, March 16, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built o

Oral presentation on preclinical data demonstrates Prothena''s dual Aβ/tau vaccine, for the potential treatment and prevention of Alzheimer''s, generated anti-Aβ and anti-tau antibodies to enable phagocytosis of Aβ and to neutralize tau Preclinical data from poster presentation demonstrates that Prothena''s tandem C-terminal α-synuclein vaccine, for the potential treatment and prevention of Parkinson''s, produces robust binding to pathogenic α-synuclein and inhibition of uptake of soluble α-synuclein aggregates into cells Oral presentation by partner Roche on the Phase 2 PASADENA study of prasinezumab, an α-synuclein antibody being developed for the treatment of Parkinson''s, further supports a potential effect on delaying motor progression in patients Prothena leadership will participate in and sponsor two AD/PD 2022 Forum Discussions: Amyloid-Removing Therapies and Anti-Tau Approaches In Clinical Trials AD/PD 2022 honors the legacy of late Prothena Co-founder and CEO, Dale Schenk Ph.D., celebrating his hallmark discoveries in the biology and advancement of therapeutics for Alzheimer''s DUBLIN, Ireland, March 16, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ: PRTA ), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, presented new preclinical data from both its dual Aβ/tau vaccine for the potential treatment and prevention of Alzheimer''s disease (AD) and from its tandem C-terminal α-synuclein vaccine programs for the potential treatment and prevention of Parkinson''s disease (PD) and related synucleinopathies.

Prothena beats on earnings and revenues in the fourth quarter of 2021. The company's progress with its AD pipeline is encouraging.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO) said the U.S. Food and Drug

Prothena beats on earnings and revenues in the fourth quarter of 2021. The company's progress with its AD pipeline is encouraging.

Prothena (PRTA) delivered earnings and revenue surprises of 4.05% and 324.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Prothena Corporation plc (PRTA) CEO Gene Kinney on Q4 2021 Results - Earnings Call Transcript

Prothena press release (PRTA): Q4 GAAP EPS of -$0.71.Revenue of $1.17M (+225.0% Y/Y).FY 2022 Guidance: The company expects the full year 2022 net cash used in operating and…

DUBLIN, Ireland, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and full year 2021. In addition, the Company provided 2022 financial guidance and an update on business highlights.

Prothena (PRTA) delivered earnings and revenue surprises of 4.05% and 324.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel In Late March Amylyx Pharma

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate